Literature DB >> 21616717

Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma.

Linda E Kelemen1, Martin Köbel.   

Abstract

Mucinous carcinomas are uncommon histological types that affect several organ sites. Primary mucinous carcinomas of the ovary are distinct from other ovarian carcinoma types, but they can pose a particular challenge for correct diagnosis from metastases, which most usually originate from the colorectum. Correct diagnosis is the mainstay of treatment, because standard practice states that protocols are tailored to the primary organ site. Little is known of mutational alterations in primary and metastatic mucinous carcinomas of the ovary, and few markers exist that can discriminate between them. We reviewed commonalities between ovarian and colorectal mucinous carcinomas with respect to aetiology, molecular alterations, differential diagnosis, and implications for treatment. Although primary mucinous carcinomas of the ovary and colorectum share similar mutational patterns and unfavourable outcomes at advanced stage, compared with their non-mucinous counterparts, important differences exist with respect to mucin localisation and specific molecular alterations. Technologies--eg, next-generation sequencing--could aid identification of additional driver molecular changes that will help clarify the relation between mucinous carcinomas from different organ sites. Perhaps, then, we can consider moving towards testing and adoption of therapeutic approaches tailored to molecular characteristics of mucinous carcinomas, irrespective of organ site, so patients' survival can be optimised.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21616717     DOI: 10.1016/S1470-2045(11)70058-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  49 in total

1.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

2.  Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.

Authors:  Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2013-12-14       Impact factor: 5.482

3.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

Review 4.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

5.  Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.

Authors:  Jennifer J Mueller; Brooke A Schlappe; Rahul Kumar; Narciso Olvera; Fanny Dao; Nadeem Abu-Rustum; Carol Aghajanian; Deborah DeLair; Yaser R Hussein; Robert A Soslow; Douglas A Levine; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2018-05-22       Impact factor: 5.482

6.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Authors:  A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

7.  Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort.

Authors:  Ulrich Nitsche; Helmut Friess; Ayman Agha; Martin Angele; Renate Eckel; Wolf Heitland; Karl-Walter Jauch; Detlef Krenz; Natascha C Nüssler; Horst-Günter Rau; Reinhard Ruppert; Gabriele Schubert-Fritschle; Dirk Wilhelm; Jens Werner; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-29       Impact factor: 4.553

8.  Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles.

Authors:  Enrica Calura; Paolo Martini; Gabriele Sales; Luca Beltrame; Giovanna Chiorino; Maurizio D'Incalci; Sergio Marchini; Chiara Romualdi
Journal:  Nucleic Acids Res       Date:  2014-05-06       Impact factor: 16.971

9.  Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes.

Authors:  Melissa A Merritt; Daniel W Cramer; Allison F Vitonis; Linda J Titus; Kathryn L Terry
Journal:  Int J Cancer       Date:  2012-07-24       Impact factor: 7.396

Review 10.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.